Biliary Tract Cancer Market Report 2026

Biliary Tract Cancer Market Overview

• Biliary Tract Cancer market size has reached to $0.72 billion in 2025 • Expected to grow to $1.01 billion in 2030 at a compound annual growth rate (CAGR) of 7% • Growth Driver: Rising Obesity Rates Fuel Growth In The Market • Market Trend: FDA Approval For Combination Therapy Marks Advancement In Biliary Tract Cancer Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Biliary Tract Cancer Market?

Biliary tract cancer (BTC), also known as cholangiocarcinoma, is a rare malignancy that arises in the bile ducts, gallbladder, or ampulla of Vater. This cancer disrupts bile flow, which plays a crucial role in digestion and waste elimination. Research and treatment efforts of biliary tract cancer focus on early detection, advancing therapeutic options, and improving survival rates for affected patients. The main types of biliary tract cancer are intrahepatic bile duct cancer, extrahepatic bile duct cancer, and gallbladder cancer. Intrahepatic cholangiocarcinoma is a rare cancer of the liver’s bile ducts that can lead to bile flow obstruction. It is treated by various treatments such as chemotherapy, targeted therapy, and immunotherapy and is used by several end users, including hospitals, specialty cancer centers, ambulatory surgical centers, and others.

What Is The Biliary Tract Cancer Market Growth Forecast?

The biliary tract cancer market size is expected to see strong growth in the next few years. It will grow to $1.01 billion in 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to increasing approvals of novel targeted drugs, rising investments in rare cancer research, growing adoption of personalized medicine, expansion of biomarker-based diagnostics, improving patient access to advanced oncology care. Major trends in the forecast period include increasing adoption of targeted therapy approaches, rising use of immunotherapy in treatment regimens, growing focus on early diagnosis and screening programs, expansion of precision oncology research, enhanced clinical trial activity for rare cancers.

Global Biliary Tract Cancer Market Segmentation

1) By Cancer Type: Intrahepatic Bile Duct Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer 2) By Treatment: Chemotherapy, Targeted Therapy, Immunotherapy 3) By End-User: Hospitals, Specialty Cancer Centres, Ambulatory Surgical Centres, Other End-Users Subsegments: 1) By Intrahepatic Bile Duct Cancer: Peripheral Intrahepatic Bile Duct Cancer, Hilar Intrahepatic Bile Duct Cancer 2) By Extrahepatic Bile Duct Cancer: Perihilar Bile Duct Cancer, Distal Bile Duct Cancer 3) By Gallbladder Cancer: Localized Gallbladder Cancer, Advanced Gallbladder Cancer

What Is The Driver Of The Biliary Tract Cancer Market?

The increasing prevalence of obesity is expected to propel the growth of the biliary tract cancer market going forward. Obesity is a chronic medical condition characterized by an excessive accumulation of body fat that can adversely affect health. The obesity prevalence increase is due to factors including physical inactivity, psychological factors, age, and genetic and biological factors. Obesity triggers chronic inflammation, insulin resistance, and excess bile acid secretion, leading to DNA damage and tumor growth. It also disrupts hormones and metabolism, fostering a cancer-prone environment in the biliary tract. For instance, in September 2024, according to the Centers for Disease Control and Prevention (CDC), a U.S.-based government agency, the number of states with adult obesity prevalence of 35% or higher rose from 22 states in 2022 to 23 states in 2023. Therefore, the increasing prevalence of obesity is driving the growth of the biliary tract cancer industry.

Key Players In The Global Biliary Tract Cancer Market

Major companies operating in the biliary tract cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Eli Lily and Company, Boehringer Ingelheim International GmbH, Eisai Co. Ltd., Servier Pharmaceuticals, Jazz Pharmaceuticals plc, Incyte Corporation, BeiGene LTD., Zymeworks, Basilea Pharmaceutica Ltd., Taiho Oncology Inc., RenovoRx Inc., TransThera Sciences Inc., QED Therapeutics Inc., Helsinn Group

Global Biliary Tract Cancer Market Trends and Insights

Major companies operating in the biliary tract cancer market are focusing on developing advanced combination treatment to enhance efficacy and improve patient outcomes. Combination therapy refers to the use of two or more medications or treatment modalities simultaneously to treat a single disease. For instance, in November 2023, Merck & Co. Inc., a US-based pharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for KEYTRUDA (pembrolizumab) in combination with gemcitabine and cisplatin for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision was based on the results from the Phase 3 KEYNOTE-966 trial, which demonstrated a statistically significant improvement in overall survival, reducing the risk of death by 17% compared to chemotherapy alone. The median overall survival for patients receiving the combination therapy was 12.7 months, compared to 10.9 months for those receiving only chemotherapy, marking this as a significant advancement in treatment options for this challenging cancer type.

What Are Latest Mergers And Acquisitions In The Biliary Tract Cancer Market?

In October 2023, Bristol Myers Squibb, a U.S.-based biopharmaceutical company developing innovative oncology and immunology medicines, acquired Mirati Therapeutics for US $4.8 billion. With this acquisition, Bristol Myers Squibb aimed to strengthen its oncology pipeline by adding Mirati’s targeted-therapy assets, including a program for MTAP-deleted tumors such as cholangiocarcinoma (bile-duct cancer), thereby improving its competitive position in rare and hard-to-treat cancers. Mirati Therapeutics is a US-based company focused on the discovery, development, and commercialization of breakthrough cancer therapies.

Regional Outlook

North America was the largest region in the biliary tract cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Biliary Tract Cancer Market?

The biliary tract cancer market consists of revenues earned by entities by providing services such as diagnosis and screening services, supportive care, clinical trials, and research. The market value includes the value of related goods sold by the service provider or included within the service offering. The biliary tract cancer market also includes sales of surgical instruments, pain management medications, and diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Biliary Tract Cancer Market Report 2026?

The biliary tract cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the biliary tract cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.